24-Jul-2026
Analysts Are Neutral on These Healthcare Stocks: Cencora (COR), Avita Medical (RCEL)
TipRanks (Tue, 21-Jul 3:50 PM ET)
TipRanks (Tue, 21-Jul 3:31 PM ET)
TipRanks (Tue, 21-Jul 3:22 PM ET)
AVITA Medical to Announce Second Quarter 2026 Financial Results
Globe Newswire (Tue, 14-Jul 4:05 PM ET)
Globe Newswire (Thu, 18-Jun 8:40 AM ET)
AVITA Medical to Host Investor Webinar Briefing
Globe Newswire (Sun, 17-May 6:00 PM ET)
RCEL Revenue Jumps on Cohealyx Surge, Costs Fall: Is AVITA Medical Turning a Corner?
Market Chameleon (Fri, 15-May 6:09 AM ET)
AVITA Medical Reports First Quarter 2026 Financial Results
Globe Newswire (Thu, 14-May 4:05 PM ET)
AVITA Medical Names Cary Vance as Chief Executive Officer
Globe Newswire (Thu, 30-Apr 8:50 AM ET)
Globe Newswire (Wed, 29-Apr 4:05 PM ET)
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
Avita Medical trades on the NASDAQ stock market under the symbol RCEL.
As of July 24, 2026, RCEL stock price was flat at $4.61 with 79,010 million shares trading.
RCEL has a beta of 0.94, meaning it tends to be less sensitive to market movements. RCEL has a correlation of 0.02 to the broad based SPY ETF.
RCEL has a market cap of $141.88 million. This is considered a Micro Cap stock.
Last quarter Avita Medical reported $19 million in Revenue and -$.35 earnings per share. This fell short of revenue expectation by $-5 million and exceeded earnings estimates by $.03.
In the last 3 years, RCEL traded as high as $21.37 and as low as $3.22.
The top ETF exchange traded funds that RCEL belongs to (by Net Assets): VTI, VXF, IWC.
RCEL has underperformed the market in the last year with a return of -22.9%, while the SPY ETF gained +17.7%. In the last 3 month period, RCEL fell short of the market, returning +3.4%, while SPY returned +3.8%. However, in the most recent 2 weeks RCEL has outperformed the stock market by returning +13.5%, while SPY returned -2.1%.
RCEL support price is $4.31 and resistance is $4.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RCEL shares will trade within this expected range on the day.